Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Sees Significant Drop in Short Interest

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 15,577 shares, a decline of 51.9% from the May 31st total of 32,362 shares. Approximately 2.8% of the company’s stock are sold short. Based on an average daily trading volume, of 23,991 shares, the short-interest ratio is presently 0.6 days.

Sigyn Therapeutics Stock Performance

Shares of OTCMKTS SIGY opened at $0.04 on Wednesday. The firm’s 50 day moving average price is $0.04 and its 200-day moving average price is $0.43. Sigyn Therapeutics has a 52-week low of $0.01 and a 52-week high of $5.00. The company has a market cap of $93,218.00, a PE ratio of -0.01 and a beta of -0.06.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.